Ding-Zhi Huang

Prof. Dr. Ding-Zhi Huang


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2018 in Cellular Physiology and Biochemistry
Verified
Journal Article
Open access
PDF file
JWJingya Wang
Jingya Wang
XGXuwen Guan
Xuwen Guan
YZYue Zhang
Yue Zhang
SGShaohua Ge
Shaohua Ge
LZLe Zhang
Le Zhang
DHDing-Zhi Huang
Ding-Zhi Huang
Background/Aims: The malignant biological behavior of gastric cancer(GC) is not only determined by cancer cells alone, but also closely regulated by the microenvironment. Fibroblasts represent a large proportion of the components in the tumor microenvironment, and they promote the development of disease. Currently, accumulating evidence suggests that exosomes can function as intercellular transport systems to relay their contents, especially microRNAs(miRNAs). Methods: First, we detected the highly-expressed level of miR-27a in exosomes isolated from gastric cancer cells by qRT-PCR. MiR-27a –over-expressed models in vitro and in vivo were established to investigate the transformation of cancer-associated fibroblasts observed by Western blotting, and the malignant behavior of gastric cancer cells using the methods CCK8 and Transwell. Moreover, the downregulation of CSRP2 in fibroblasts was used to evaluate the promotion of malignancy of gastric cancer using the methods CCK8 and Transwell. Results: In this study, we found a marked high level of miR-27a in exosomes derived from GC cells. miR-27a was found to function an oncogene that not only induced the reprogramming of fibroblasts into cancer-associated fibroblasts(CAFs), but also promoted the proliferation, motility and metastasis of cancer cells in vitro and in vivo. Conversely, CAFs with over-expression of miR-27a could pleiotropically increase the malignant behavior of the GC cells. For the first time, we revealed that CSRP2 is a downstream target of miR-27a. CSRP2 downregulation could increase the proliferation and motility of GC cells. Conclusion: Thus, this report indicates that miR-27a in exosomes derived from GC cells has a crucial impact on the microenvironment and may be used as a potential therapeutic target in the treatment of GC

1 June 2016 in Cancer Letters
Verified
Journal Article
Closed access
HZHaiyang Zhang
Haiyang Zhang
MBMing Bai
Ming Bai
TDTing Deng
Ting Deng
RLRui Liu
Rui Liu
XWXia Wang
Xia Wang
YBYi Ba
Yi Ba

12 January 2016 in Protein & Cell
Verified
Journal Article
Open access
PDF file
HZHaiyang Zhang
Haiyang Zhang
JDJingjing Duan
Jingjing Duan
YQYanjun Qu
Yanjun Qu
TDTing Deng
Ting Deng
RLRui Liu
Rui Liu
YBYi Ba
Yi Ba
Gastric cancer is one of the most common malignancies worldwide; however, the molecular mechanism in tumorigenesis still needs exploration. BCL2L11 belongs to the BCL-2 family, and acts as a central regulator of the intrinsic apoptotic cascade and mediates cell apoptosis. Although miRNAs have been reported to be involved in each stage of cancer development, the role of miR-24 in GC has not been reported yet. In the present study, miR-24 was found to be up-regulated while the expression of BCL2L11 was inhibited in tumor tissues of GC. Studies from both in vitro and in vivo shown that miR-24 regulates BCL2L11 expression by directly binding with 3′UTR of mRNA, thus promoting cell growth, migration while inhibiting cell apoptosis. Therefore, miR-24 is a novel onco-miRNA that can be potential drug targets for future clinical use.

23 August 2013 in Platelets
Verified
Journal Article
Closed access
HWHaiyan Wang
Haiyan Wang
JGJinbiao Gao
Jinbiao Gao
MBMing Bai
Ming Bai
RLRui Liu
Rui Liu
HLHongli Li
Hongli Li
YBYi Ba
Yi Ba
Cancer patients frequently present with activated coagulation pathways and thrombocytosis, which are potentially associated with tumor progression and prognosis. However, the prognostic value of abnormal plasma fibrinogen and platelet levels for the treatment of pancreatic cancer is unclear. The purpose of our study was to evaluate the prognostic value of plasma fibrinogen and platelet levels in pancreatic cancer, and to devise a prognostic model to identify the patients with greatest risk for a poor overall survival. One hundred and twenty-five patients diagnosed with pancreatic ductal adenocarcinoma in our hospital between May 2000 and June 2005 were included in this study. The plasma fibrinogen and platelet levels were examined before treatment and analyzed along with patient clinicopathological parameters and overall survival. The foundation of prognostic model was based on the risk factors according to the Cox proportional hazard model. The incidence of hyperfibrinogenemia and thrombocytosis was 24.8% (31/125) and 15.2% (19/125), respectively. The mean fibrinogen concentration differed significantly between the early (I/II) and late (III/IV) stage patients (3.19 ± 0.70 vs. 3.65 ± 0.90 g/l, p = 0.008). Patients with a higher concentration of plasma fibrinogen and platelets had a worse prognosis (p < 0.05). There also existed a significant correlation between higher fibrinogen/platelet levels and distant organ metastasis (p < 0.05, respectively). Bivariate correlation analysis showed that plasma fibrinogen levels correlated significantly with platelet levels (p = 0.000). Multivariate analysis revealed that pretreatment plasma fibrinogen levels (p = 0.027), tumor stage (p = 0.026) and distant metastasis (p = 0.027) were independent prognostic factors. The median survival time for the low-, intermediate-, and high-risk groups was 9.6 months (95% CI 6.2–13.0), 3.8 months (95% CI 2.3–5.3), and 2.3 months (95% CI 0.9–3.7), respectively (p = 0.000). Pretreatment plasma fibrinogen and platelet levels closely correlated with tumor progression, metastasis and overall survival in pancreatic cancer. The foundation of prognostic model may help us identify the greatest risk populations with pancreatic cancer.

28 October 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
RLRui Liu
Rui Liu
HZHaiyang Zhang
Haiyang Zhang
XWXia Wang
Xia Wang
LZLikun Zhou
Likun Zhou
HLHongli Li
Hongli Li
YBYi Ba
Yi Ba
The miR-24-Bim pathway promotes tumor growth and angiogenesis in pancreatic carcinoma

1 April 2021 in Cancer Letters
Verified
Journal Article
Closed access
JWJingya Wang
Jingya Wang
TSTao Sun
Tao Sun
ZMZhaoting Meng
Zhaoting Meng
LWLiuchun Wang
Liuchun Wang
MLMengjie Li
Mengjie Li
DHDing-Zhi Huang
Ding-Zhi Huang